KORU Medical Systems (NASDAQ:KRMD – Get Free Report) and Cytosorbents (NASDAQ:CTSO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership.
Institutional & Insider Ownership
58.6% of KORU Medical Systems shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 25.6% of KORU Medical Systems shares are held by insiders. Comparatively, 6.6% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares KORU Medical Systems and Cytosorbents’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| KORU Medical Systems | -37.42% | -24.60% | -16.87% |
| Cytosorbents | -49.47% | -118.54% | -42.31% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| KORU Medical Systems | $31.99 million | 5.63 | -$13.74 million | ($0.25) | -15.72 |
| Cytosorbents | $36.35 million | 1.31 | -$28.51 million | ($0.36) | -2.42 |
KORU Medical Systems has higher earnings, but lower revenue than Cytosorbents. KORU Medical Systems is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
KORU Medical Systems has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and price targets for KORU Medical Systems and Cytosorbents, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| KORU Medical Systems | 0 | 0 | 3 | 1 | 3.25 |
| Cytosorbents | 0 | 1 | 1 | 1 | 3.00 |
KORU Medical Systems currently has a consensus target price of $4.13, indicating a potential upside of 4.96%. Cytosorbents has a consensus target price of $2.00, indicating a potential upside of 129.46%. Given Cytosorbents’ higher probable upside, analysts plainly believe Cytosorbents is more favorable than KORU Medical Systems.
Summary
KORU Medical Systems beats Cytosorbents on 10 of the 14 factors compared between the two stocks.
About KORU Medical Systems
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
About Cytosorbents
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for KORU Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KORU Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
